MEK 162
Showing 1 - 25 of 297
Gastrointestinal Stromal Tumor (GIST) Trial in New York (drug, other, procedure)
Active, not recruiting
- Gastrointestinal Stromal Tumor (GIST)
- MEK162
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 28, 2022
Melanoma Stage III, Melanoma Stage IV Trial in San Francisco (Binimetinib, Imatinib)
Recruiting
- Melanoma Stage III
- Melanoma Stage IV
-
San Francisco, CaliforniaUniversity of California, San Francisco
Dec 6, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8 Trial in
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +2 more
- Binimetinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Leukemia Trial in Houston (MEK 162)
Terminated
- Leukemia
- MEK 162
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Mar 25, 2021
Malignant Solid Tumor, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma Trial (Binimetinib, Biopsy, Biospecimen
Not yet recruiting
- Malignant Solid Neoplasm
- +4 more
- Binimetinib
- +6 more
- (no location specified)
Nov 8, 2022
Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Tumor Trial in Buffalo (Binimetinib, Palbociclib, Therapeutic
Recruiting
- Colorectal Carcinoma
- +3 more
- Binimetinib
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
May 11, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Boston, Galveston,
Suspended
- Advanced Malignant Solid Neoplasm
- +4 more
- BET Bromodomain Inhibitor ZEN-3694
- Binimetinib
-
Boston, Massachusetts
- +2 more
Oct 5, 2022
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,
Recruiting
- BRAF NP_004324.2:p.V600M
- +6 more
- Binimetinib
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Aug 17, 2022
Solid Tumors Harboring a BRAF V600 Mutation Trial in Worldwide (LGX818, MEK162, LEE011)
Active, not recruiting
- Solid Tumors Harboring a BRAF V600 Mutation
- LGX818
- +2 more
-
Tampa, Florida
- +22 more
Mar 16, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast
Not yet recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Binimetinib
- +5 more
- (no location specified)
Nov 8, 2022
Gastrointestinal Stromal Tumor (GIST) Trial in New York (MEK162, Pexidartinib)
Completed
- Gastrointestinal Stromal Tumor (GIST)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 29, 2021
BRAF or NRAS Mutant Metastatic Melanoma Trial in Worldwide (MEK162)
Active, not recruiting
- BRAF or NRAS Mutant Metastatic Melanoma
-
Fayetteville, Arkansas
- +20 more
Nov 18, 2021
Advanced Biliary Tract Carcinoma Trial in New York (Gemcitabine, Cisplatin, MEK162)
Completed
- Advanced Biliary Tract Carcinoma
- Gemcitabine
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 26, 2020
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Terminated
- Metastatic Colon Adenocarcinoma
- +27 more
- Binimetinib
- +3 more
-
San Francisco, California
- +1 more
Jan 5, 2023
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma Trial in Guangzhou (BYL719, INC280, LDK378)
Completed
- Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
- BYL719
- +3 more
-
Guangzhou, Guangdong, ChinaNovartis Investigative Site
Nov 20, 2020
Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7 Trial in Jacksonville (drug,
Active, not recruiting
- Breast Adenocarcinoma
- +6 more
- Binimetinib
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Dec 14, 2021
Solid Tumor, Colorectal Cancer Trial in Oxford (PF-02341066, PD-0325901, Binimetinib)
Completed
- Solid Tumor
- Colorectal Cancer
- PF-02341066
- +2 more
-
Oxford, United KingdomOxford University Hospital NHS Trust
Jun 14, 2021
Metastatic Colorectal Cancer Trial in Worldwide (MEK162, Panitumumab)
Completed
- Metastatic Colorectal Cancer
-
Los Angeles, California
- +7 more
Jan 27, 2021
Recurrent Melanoma, Stage IV Melanoma Trial in Los Angeles (Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker
Withdrawn
- Recurrent Melanoma
- Stage IV Melanoma
- Raf kinase inhibitor LGX818
- +2 more
-
Los Angeles, CaliforniaJonsson Comprehensive Cancer Center
Jul 23, 2020
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma Trial in Worldwide (MEK162, AMG 479)
Terminated
- Metastatic Pancreatic Adenocarcinoma
- BRAF Mutated Melanoma
- MEK162
- AMG 479
-
Boston, Massachusetts
- +8 more
Dec 9, 2020